Riskpilot← Back to searchSign inGet full accessCytiva Denmark ApS
APSActiveCVR 43126261Åkandevej 21Wholesale of pharmaceutical and medical goods · NACE 4646Est. 202228 employees
Revenue 2024
DKK 1,7B
+1629% vs 2023
EBITDA margin
5.9%
+21% vs 2023
Equity ratio
46.9%
Financial strength
Net profit 2024
DKK 80,5M
+22% vs 2023
| Revenue | DKK 1,7B | +1629% |
| EBITDA | DKK 102,7M | +21% |
| Net profit | DKK 80,5M | +22% |
| Total assets | DKK 574,4M | +6% |
| Equity | DKK 269,3M | +43% |
| Employees | 28 | — |
Legal name
Cytiva Denmark ApS
CVR number
43126261
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
15. marts 2022
Share capital
DKK 50.000
Employees
28 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af én direktør.
Company purpose
Selskabets formål omfatter, men er ikke begrænset til, følgende aktiviteter: salg, distribution, handel, indkøb, forskning, udvikling, support, design, konstruktion, fremstilling, installation, licensudstedelse, leasing og servicering. Disse aktiviteter udføres hovedsageligt i relation til videnskabeligt udstyr, filtrerings-, rensnings- og separationsteknologier, kemikalier, digital- og softwareteknologier og andet relateret tilbehør og produkter. Selskabet opererer primært inden for områderne life science, bioteknologi, biologiske behandling, medicin og hospitaler, biofarmaceutiske produkter og fødevarer og drikkevarer.
Selskabet kan engagere sig i enhver virksomhed, som direkte eller indirekte tjener Selskabets formål. Selskabet kan etablere filialer og deltage i lignende virksomheder.
Address
Åkandevej 21
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | 0 | 101.051 | 1.747.415 |
| Staff expenses | -0 | -15.999 | -26.559 |
| EBITDA | 0 | 85.051 | 102.745 |
| Depreciation & amort. | -0 | -0 | -0 |
| EBIT | 0 | 85.051 | 102.745 |
| Net financials | -0 | 69 | 811 |
| Profit before tax | -0 | 85.120 | 103.556 |
| Tax | -0 | 18.866 | 23.014 |
| Net profit | -0 | 66.254 | 80.542 |
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total assets | 250 | 543.770 | 574.402 |
| Equity | 250 | 188.723 | 269.265 |
| Long-term debt | 0 | 0 | 1.048 |
| Short-term debt | 0 | 352.892 | 301.068 |
| Total debt | 0 | 352.892 | 302.115 |
EBITDA margin
5.9%
This company
15.8%
Market median
-63% vs market
20222024
Equity ratio
46.9%
This company
38.2%
Market median
+23% vs market
20222024
Return on equity
29.9%
This company
18.4%
Market median
+63% vs market
20222024
Net profit margin
4.6%
This company
8.1%
Market median
-43% vs market
20222024
Asset turnover
3.04×
This company
1.12×
Market median
+171% vs market
20222024
Debt / equity
1.13×
This company
0.62×
Market median
-82% vs market
20222024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-03-15 – 2022-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PJ Management | Management | 2026 | — | — |
NT Management | Management | 2023 | — | — |
MA Management | Management | 2023 | — | — |
NP Management | Management | 2022 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Cytiva Denmark ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Jonas Jakstad | Management | 0 companies |
| Nils Tomas Ljunggren | Management | 0 companies |
| Marinus Adrianus Johannes Hazenberg | Management | 0 companies |
| Nicolaj Peter Saxild | Management | 0 companies |